Suppliers / Qingdao Jiulong Biopharmaceutical

Qingdao Jiulong Biopharmaceutical

China Updated 9 July 2026

Qingdao Jiulong Biopharmaceutical is an API manufacturer based in China. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 13 March 2015 as NAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 13 March 2015 NAI US FDA
  • 18 March 2011 VAI US FDA
  • 23 November 2009 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3006745882

What they file, and where

Molecule Regulators Docs
Heparin Sodium US FDA 1

Also appears on these molecule pages

Heparin API

Comparing suppliers?

Choose your molecules and target markets. Qingdao Jiulong Biopharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 13 March 2015.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability